Table 1.
eGFR before and after 2 yr of weekly treatment with agalsidase alfaa
| Patient | Age (yr) | eGFR (ml/min per 1.73 m2) Pre-EOW | Duration of EOW (yr) | eGFR (ml/min per 1.73 m2)
|
|
|---|---|---|---|---|---|
| Weekly Study Entry | Weekly Study 2 yr | ||||
| 1 | 43.7 | 68.7 | 4.0 | 28.7 | 17.8 |
| 2 | 49.9 | 48.2 | 4.5 | 24.6 | 15.9 |
| 3 | 48.5 | 87.1 | 4.0 | 62.5 | 83.9 |
| 6 | 24.1 | 142.6 | 4.5 | 79.0 | 60.1 |
| 7 | 36.8 | 82.5 | 4.5 | 66.1 | 79.3 |
| 8 | 44.2 | 112.5 | 2.5 | 77.2 | 76.5 |
| 9 | 52.9 | 51.1 | 4.5 | 42.2 | 41.9 |
| 10 | 45.1 | 70.0 | 2.0 | 63.4 | 49.5 |
| 11 | 41.1 | 59.7 | 2.0 | 47.4 | 38.9 |
| 12 | 38.0 | 40.3 | 2.0 | 25.0 | 18.8 |
| 14 | 31.5 | 93.6 | 2.5 | 74.8 | 73.9 |
| Mean | 41.4 | 77.8 | 3.4 | 53.7 | 50.6 |
| SD | 8.4 | 30.4 | 1.1 | 21.0 | 26.0 |
a
eGFR, estimated GFR; pre-EOW, baseline before beginning every other week dosing.